Core Viewpoint - Monte Rosa Therapeutics experienced a pre-market surge of over 42%, reaching $22.76, following positive mid-stage results from its MRT-8102 Phase I trial, which demonstrated a significant reduction in C-reactive protein levels in cardiovascular and cardiometabolic disease patients [1] Group 1: Clinical Trial Results - The MRT-8102, a NEK7-targeted molecular glue degrader in development for treating NLRP3/IL-1/IL-6 driven inflammatory diseases, showed rapid and sustained systemic inflammation reduction effects [1] - After four weeks of treatment with MRT-8102, C-reactive protein (CRP) levels decreased by 85%, with 94% of participants achieving CRP levels below 2 mg/L, a threshold associated with reduced cardiovascular disease (CVD) risk [1]